Dotmatics

Portfolio | Dotmatics

Dotmatics is the largest provider of R&D software for scientists and labs, offering a comprehensive portfolio of AI-driven tools—including Luma, GraphPad Prism, Geneious, SnapGene, EasyPanel, FCS Express, LabArchives, M-Star, and Statsols—that support diverse scientific workflows such as data analysis, genomics, assay development, flow cytometry, cloning, computational fluid dynamics, and clinical trial design to accelerate life-changing discoveries by enabling faster, more accurate data-to-insight decision making.

Dotmatics is the largest provider of R&D software for scientists and labs, supporting data analysis, genomics, assay development, flow cytometry, sequence analysis, cloning, computational fluid dynamics, protein characterization, materials development, formulations, and more.

All products in the Dotmatics portfolio are designed to enable scientists to connect science and data, accelerating AI-driven decision making in multimodal research and development. By helping scientists accurately turn data into insights and make better decisions faster, Dotmatics aims to accelerate life-changing discoveries.

Dotmatics Brands

  • Luma: An AI-native multimodal scientific intelligence platform designed to adapt to unique scientific workflows and data structures.
  • GraphPad Prism: A versatile statistics tool purpose-built for scientists, simplifying the analysis, graphing, and presentation of scientific research.
  • Geneious Prime and Geneious Biologics: Intuitive yet powerful software applications for DNA data analysis and visualization.
  • SnapGene: A popular cloning tool offering an easy way to plan, visualize, and document core molecular biology procedures.
  • EasyPanel: Biotech software offering an intelligent and automated flow cytometry panel designer, utilizing a proprietary algorithm to suggest optimized panels based on a customer's test environment.
  • De Novo's FCS Express: An integrated analysis, statistics, graphing, and reporting tool focused on turning raw flow cytometry and image cytometry data into presentation-ready results.
  • LabArchives: An Electronic Lab Notebook data management solution enabling scientists to document data, prove and protect discovery, and collaborate securely.
  • M-Star: Computational fluid dynamics (CFD) software offering robust and scalable simulation solutions tailored for engineering applications.
  • Statsols (nQuery): Owner of nQuery, a trusted clinical trial design platform and proprietary sample size software.
  • OMIQ: A modern cytometry analysis platform bridging machine learning and analytical pipelines with classical manual analysis, allowing researchers to go from raw data to statistical significance in one software.
  • Protein Metrics: Provider of proteomics analysis software for highly-accurate analyses on data from all major mass spectrometry platforms.
  • SoftGenetics: Bioinformatics software offering advanced genetic analysis products for research, forensics, and healthcare applications.
  • Virscidian (Analytical Studio): Advanced informatics solution simplifying complex, high-throughput chromatography and mass spectrometry data, automating small molecule data analysis and guiding experimental steps.

Strategic Investments

  • BioGlyph: Startup biotech software company developing technology to visually illustrate, register, and model biologic molecules, including multispecific antibodies.
  • Modicus Prime: Provides intelligent image analysis of biologics, enabling scientists to train their own AI for real-time classification of imaging data, supporting quality control across R&D and manufacturing.

What our customers are saying

“Geneious is an absolutely beautiful package to work with. We love it and we are telling everyone about it.”

— Charles Moore, Novartis Pharma AG, Switzerland

“I have used Prism and many of its competitors extensively and I think Prism is by far the most intuitive and approachable software of its class.”

— Jessica H. Hartman, Ph.D, Duke University

“Solutions like Dotmatics are enabling organisations like ours to raise the academic game to another level.”

— Julian Blagg, Institute of Cancer Research